Whole genome sequencing and phylogenetic analysis of six SARS-CoV-2 strains isolated during COVID-19 pandemic in Tunisia, North Africa

Wasfi Fares1*, Anissa Chouikha1, Kais Ghedira2, Meriam Gdoura1, Dora Rezig1, Sondes Haddad Boubaker1, Imen Ben Dhifallah1, Henda Touzi1, Walid Hammami1, Zina Meddeb1, Amel Sadraoui1, Nahed Hogga1, Imen Abouda1, Aurélie Kwasiborski3, Véronique Houdet3, Guillaume Mikaty3, Valérie Caro3, Jean-Claude Manuguerra3, Nissaf Ben Alaya4,5 and Henda Triki1,5

Abstract

Background: In Tunisia a first SARS-CoV-2 confirmed case was reported in March 03, 2020. Since then, an increase of cases number was observed from either imported or local cases. The aim of this preliminary study was to better understand the molecular epidemiology and genetic variability of SARS-CoV-2 viruses circulating in Tunisia and worldwide.

Methods: Whole genome sequencing was performed using NGS approach on six SARS-CoV-2 highly positive samples detected during the early phase of the outbreak.

Results: Full genomes sequences of six Tunisian SARS-CoV-2 strains were obtained from imported and locally transmission cases during the COVID-19 outbreak. Reported sequences were non-identical with 0.1% nucleotide divergence rate and clustered into 6 different clades with worldwide sequences. SNPs results favor the distribution of the reported Tunisian sequences into 3 major genotypes. These SNP mutations are critical for diagnosis and vaccine development.

Conclusions: These results indicate multiple introductions of the virus in Tunisia and add new genomic data on SARS-CoV-2 at the international level.

Keywords: Whole genome sequencing, SARS-CoV-2, SNPs, Genotype, Tunisia

Background

Human Coronaviruses (HCoV’s) are members of the subfamily Coronavirinae in the family of Coronaviridae in the order of Nidovirales. Since 1960s, six different HCoV’s were identified; two belongs to the genus Alpha-coronavirus (229E, NL63) and four to the genus Betacoronavirus (HKU1 and OC43, SARS-CoV, MERS-CoV). Similarly to other coronaviruses, SARS-CoV-2 is an enveloped, single-stranded positive-sense RNA (~29,900 nt) with 5’-cap structure and 3’-poly-A tail [1].

In December 2019, a novel Human Coronavirus (HCoV) associated to severe acute respiratory syndrome was discovered in the city of Wuhan, Hubei province, China and was later named SARS-CoV-2 [2, 3]. The outbreak of the coronavirus disease (COVID-19) spread further worldwide and the World Health Organization

* Correspondence: fwasfi@yahoo.fr
1 Laboratory of Clinical Virology, Institut Pasteur, University Tunis-El Manar, Tunis, Tunisia
Full list of author information is available at the end of the article

© The Author(s). 2021 Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
(WHO) officially declared the pandemic aspect of the COVID-19 epidemic on March 12th, 2020 [4]. The WHO report dated on June 21st, 2020 confirmed 8,708,008 cases of SARS-CoV-2 with 461,715 deaths from 215 countries and territories [5].

The Tunisian government, through the Ministry of Health (MoH) and the National Observatory of New and Emerging Diseases, reviewed and initiated multisectoral measures to deal with the COVID-19 epidemic. The national strategy aims early detection of imported cases, isolation of confirmed cases as well as suspected cases. Moreover, the MoH commit to develop diagnostic and treatment procedures in order to limit the spread of the SARS-CoV-2 within the population and avoid exceeding of the health system capacity. These measures allowed the Tunisian authorities to identify the first SARS-CoV-2 in March 03, 2020 [6]. As of June 7th, a total of 1,087 COVID-19 cases, including 286 imported and 801 locally transmitted cases, have been diagnosed and tested positive for SARS-CoV-2 with 49 deaths [7].

This work reports the first whole genome sequences of the SARS-CoV-2 viruses isolated in Tunisia during the early phase of the outbreak. Phylogenetic comparison with whole genome sequences reported from other countries and single-nucleotide polymorphism (SNPs) were assessed.

Results

The six Tunisian sequences obtained were 29,541 to 29,825 nucleotide-long and covered the whole coding region and more than 99.1% of the genome. The totality of complete genome sequences available at writing time, of SARS-CoV-2 were downloaded from the GISAID (http://www.gisaid.org/) and the NCBI (http://www.ncbi.nlm.nih.gov/genbank) databases. All the repeated sequences as well as the sequences with missing regions have been excluded. The 268 selected sequences originated from 61 different countries worldwide. The phylogenetic tree in Fig. 1, shows that Tunisian SARS-CoV-2 sequences were scattered independently of each other in different clusters including strains mainly from Europe and Asia (Fig. 1a). Three out of six Tunisian sequences clustered with sequences from France: one case came from France (COV0425, Fig. 1g) and two were locally infected (COV1482 and COV1663, Fig. 1d and e). The sequence COV1339 was isolated from a case coming from Turkey, it grouped with sequences originated from Taiwan, Egypt and Finland (Fig. 1f). Sequence COV0010 was from a case with recent travel to Vietnam and clustered with sequences from Thailand, Vietnam, China and Japan (Fig. 1b). The last identified sequence COV0880 was from a locally infected individual and grouped with sequences from Turkey, Belarus and Kuwait (Fig. 1c).

The Tunisian SARS-CoV-2 retrieved full genome sequences alignment with the Wuhan reference sequences (NC045512) were used for the investigation of the SNPs and the resulting variable amino-acids composition throw genome detective web server (https://www.genomedetective.com/); the obtained results are shown in Table 1.

The average and the Min/Max depth of coverage for the six described isolates was as follows, Cov0010: 12545 (0/35320), Cov0880: 9339 (0/41049), Cov1339: 10456 (0/
| Gene   | nsp2 | nsp 3 | nsp4 | nsp6 | nsp7 | nsp8 | nsp12 | nsp13 | nsp14 | Orf3a | Orf8 | N       |
|--------|------|-------|------|------|------|------|-------|-------|-------|-------|------|---------|
| Nucleotide position | 1059 | 1397  | 1666 | 2113 | 3037 | 3896 | 4288  | 5557  | 7420  | 8371  | 9547 | 10,046 |
| Cov0010 SNPs mutations | T>C  | C>T   | C>T  |        |      |      |       |       |       |       |      |         |
| Proteins mutations |        |        | G946G |      |      |      |       |       |       |       |      |         |
| Cov0880 SNPs mutations | G>A  | G>T   | G>T  | A>G  | G>A  | A>C  |       |       |       |       |      |         |
| Proteins mutations | V198I | E523D | G309C | L320L | V498I | L37F | F155A |       |       |       |      |         |
| Cov1399 SNPs mutations | C>T  | C>T   | C>T  | C>T  | C>T  |       |       |       |       |       |      |         |
| Proteins mutations |        |        |        | L436L | F105F |      |       |       |       |       |      |         |
| Cov1663 SNPs mutations | C>T  | G>T   | C>T  | A>C  | C>T  | C>T  |       |       |       |       |      |         |
| Proteins mutations | F105F | Y393F |        |       |       | O31H | P323L | N628N |       |       |      |         |
| Cov0425 SNPs mutations | C>T  | C>T   |       |       |       |       |       |       |       |       |      |         |
| Proteins mutations |        |        | Y537Y | F105F |      |       |       |       |       |       |      |         |
| Cov1482 SNPs mutations | C>T  | T>C   | C>T  | C>T  |       |       |       |       |       |       |      |         |
| Proteins mutations | T85I | F/287F | F105F |       |       |       |       |       |       |       |      |         |
| Gene   | nsp13 | nsp14 | Orf3a | Orf8 | N       |
| Nucleotide position | 17,690 | 18,523 | 18,877 | 19,525 | 20,032 |
| Cov0010 SNPs mutations | G>T  | T>C   | G>A  |       |       |
| Proteins mutations | T302T | L84S  | S102N |       |       |
| Cov0880 SNPs mutations | T>A  | A>C   | G>T  | T>C  |       |
| Proteins mutations | Y279N | I7L   | M11  |       |       |
| Cov1399 SNPs mutations | C>T  | C>T   | G>T  | C>T  | A>G  | A>G  | G>T  |       |       |       |      |         |
| Proteins mutations | S485L | L280L | D489Y | P216L | A288T | C291C | Q314R | D614G | Q57H |      |         |
| Table 1 | Single nt polymorphisms (SNPs) deduced by comparison of six Tunisian whole genome SARS-CoV-2 sequences with reference SARS-CoV-2 NC045512 (Continued) |
|---------|------------------------------------------------------------------------------------------------------------------|
| Cov1663 | SNPs mutations                                                                                                      |
|         | G > T                                                                                                              |
| Proteins mutations | C > T | C > T                                                                                                             |
|         | A > G                                                                                                              |
|         | V162L                                                                                                              |
|         | R138C                                                                                                              |
|         | T29I                                                                                                                |
|         | D614G                                                                                                               |
| Cov0425 | SNPs mutations                                                                                                      |
|         | A > G                                                                                                              |
| Proteins mutations | G > T                                                                                                             |
|         | D614G                                                                                                              |
|         | Q57H                                                                                                                |
| Cov1482 | SNPs mutations                                                                                                      |
|         | A > G                                                                                                              |
| Proteins mutations | G > T                                                                                                             |
|         | G > T                                                                                                              |
|         | G > T                                                                                                              |
|         | D614G                                                                                                              |
|         | Q57H                                                                                                                |
|         | G25F                                                                                                                |
|         | G25F                                                                                                                |

(In bold and underlined: confirmed mutations with more than 2500 reads. In italics: validated mutations with less than 2500 reads)
The six Tunisian SARS-CoV-2 sequences were non-identical with 0.1% nucleotide divergence between each other. Compared to the Wuhan (NC045512) reference, the reported Tunisian SARS-CoV-2 sequences showed several synonymous and non-synonymous mutations, distributed over the entire genome. A total of 43 SNP mutations were identified with 27 and 16 SNPs in the non-structural and structural region respectively. Each sequence showed a different SNPs profile; the number of detected SNPs in each sequence ranged between 6 and 13. Most of them were located in the non-structural region affecting 08 out of the 16 non-structural genes (Table 1). In the structural region, most of SNPs were detected in the S gene encoding for the spike protein.

**Discussion**

In this work, the full genomes sequences of six SARS-CoV-2 strains were obtained from RT-PCR positive samples collected in Tunisian patients between March and April 2020. Three cases had a recent travel history, one coming from Vietnam, one from Turkey and one from France; while the three remaining cases were infected locally through horizontal transmission. The six sequences were non-identical with 0.1% nucleotide divergence between each other and had several nucleotide changes compared to the first published COVID-19 sequence from Wuhan, China (NC045512). Phylogenetic analysis including representative sequences from 61 countries split the six sequences from Tunisia into 6 different clusters, together with sequences from various other countries. These results indicate multiple introductions of the SARS-CoV-2 virus in Tunisia.

According to recently published results by Yin in 2020, four major genotypes were suggested depending on the positions of SNPs [8]. The SNPs here reported in the positions 3037, 8782, 11,083, 14,408, 23,403 and 28, 144 allowed us to classify the Tunisian sequences into 3 distinct genotypes among the four major genotypes described: Genotype I (COV0880), genotype III (COV0010) and Genotype IV (COV0425, COV1339, COV1482 and COV1663). Indeed, these SNPs were identified as the most frequent mutations described since of the beginning of the pandemic in comparison with the Wuhan reference SARS-CoV-2 genome NC045512.2 [8, 9]. The highly frequent SNP mutations was previously described in the S protein, RNA polymerase, RNA primase, and nucleoprotein, which are critical proteins for diagnosis and vaccine development [8, 10].

Further complementary studies including clinical status of COVID-19 cases will be of great interest to better understand the impacts of these SNP mutations on the transmissibility and pathogenicity of SARS-CoV-2.

**Conclusions**

Analysis of SARS-CoV-2 sequences from the maximum of affected countries and in different phases of the COVID-19 outbreak is crucial to understand the virus transmission and its genetic evolution through time. This preliminary study reports the first SARS-CoV-2 whole genome sequences from Tunisia, North Africa. Further sequences from different clinical and epidemiological settings are still needed to monitor the molecular epidemiology of SARS-CoV-2 in the country and worldwide.

**Methods**

Detection of SARS-CoV-2 infection was performed on nasopharyngeal swabs samples by specific real time reverse transcription polymerase chain reaction (RT-PCR) according to the WHO approved protocol published by Corman et al. and detecting specific sequences in the E, N and RdRp genes [11]. A total of 6 SARS-CoV-2 highly positive samples were assessed for whole genome sequencing using the NGS approach. The respective COVID-19 cases were detected between March and April 2020. They originated from six different districts of Tunisia. Three cases had recent travel history and three were infected locally.

A total of 140 μl of each nasopharyngeal sample was used for RNA extraction via the Qiam viral RNA mini kit (Qiagen, Hilden, Germany). Reverse transcription of the whole genome was performed by The ProtoScript II First Strand cDNA synthesis kit (New England Biolabs, USA) using random hexamers. For the multiplex PCR approach, the general method described in (https://artic.network/nCoV-2019) was applied using Version 3 of amplicon set. After 40 amplification cycles, the PCR products were cleaned-up with AMPure XP magnetic beads (Beckman Coulter, USA) and quantified with the Qubit 2.0 fluorometer (ThermoFisher Scientific, USA).

The Nextera DNA Flex Prep kit (Illumina, USA) was used for library preparation and thereafter qualified on an Agilent Technologies 2100 Bioanlyser using a high-sensitivity DNA chip following the manufacturer’s instructions. Generated libraries were sequenced using the MiSeq System (Illumina, USA) providing 2 × 250 bp read length data.

To remove low quality reads, trim off low-quality and contaminant residues and filter out duplicated reads, fqCleaner v.0.5.0 was used, with Phred quality score of 28. Filtered reads were mapped against SARS-CoV-2 reference (NC045512) using Burrows-Wheeler Aligner.
MEM algorithm (BWA-MEM) (v0.7.7). SAM tools were used to sort BAM files, to generate alignment statistics and to obtain coverage data. Whole genome sequences of the six SARS-CoV-2 Tunisian strains were submitted to NCBI database under accession number MT499215 to MT499220.

Multiple sequences alignment was performed using Multiple Sequence Comparison by Log- Expectation (MUSCLE) software implemented in Molecular Evolutionary Genetics Analysis software (MEGA) version 7 [12]. Phylogenetic analysis was performed using the neighbor-joining analysis method and the Kimura 2-parameter model with 1000 bootstrap replications. Genetic distances were calculated using the p-distance method.

**Abbreviations**

COMID: Corona Virus Disease; GISAID: Global Initiative on Sharing Avian Influenza Data; MEGA: Molecular Evolutionary Genetics Analysis software; MUSCLE: Multiple Sequence Comparison by Log-Expectation; NGS: New generation Sequencing; RNA: Ribonucleic Acid; RT-PCR: Reverse transcription polymerase chain reaction; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; SNPs: Single Nucleotides Polymorphism; SRA: Sequence Read Archive.

**Acknowledgments**

The authors thank the field staff from the Ministry of Health for their efforts in specimen collection and transportation to the laboratory. The authors thank also all the IHP volunteers who worked very hard to manage the huge number of samples from the reception to the result reporting.

**Authors’ contributions**

WF Conceptualization and writing the original draft. AC contributing in writing the original draft. KG Formal Analysis and writing the original draft. MG Reviewing and editing. DR: Investigation process. S H-R: Investigation process. IBD Investigation process. HT Investigation process. WH Investigation process. ZM Investigation process. AS: Investigation process. NH: Investigation process. IA: Investigation process. AK: Formal analysis. VH: Formal Analysis.

**Funding**

This work was supported by the Tunisian Ministry of High Education and Research and the MediLabSecure Project, founded by the European Commission (DEVCO: IFS/2018/402–247).

**Availability of data and materials**

The six SARS-CoV-2 Tunisian strains sequences, obtained in the current study, were submitted to NCBI database and the accession number with the corresponding strains is as follow: MT499215, MT499216, MT499217, MT499218, MT499219 and MT499220 for strains COV0010, COV0880, COV1339, COV1663, COV0425 and COV1482, respectively (https://www.ncbi.nlm.nih.gov/nuccore/MT499215,MT499216,MT499217,MT499218,MT499219,MT499220). The raw reads datasets generated and analyzed during the current study were submitted to the NCBI Sequence Read Archive (SRA) repository and freely available under following accession numbers SRX11188766 to SRX11188771 for the corresponding whole genome sequence MT499215 to MT499220 respectively. The SARS-CoV-2 isolate Wuhan-Hu-1 sequence used as a reference strain is available on the https://www.ncbi.nlm.nih.gov/nuccore/NC_045512.

**Declarations**

**Ethics approval and consent to participate**

Our work was a retrospective analysis of already available samples collected as part of the COVID-19 diagnostic effort, and all samples used for analysis were anonymized. This work was approved by the ethical institutional review board “Comité d’Ethique Bio-Médicale (CEBM)” from the Institut Pasteur de Tunis (ref.2020/14/LR16PTA/1). Consequently, our institutional Review Board (IRB) deemed it unnecessary to obtain ethics approval for this work. The need for consent was also deemed unnecessary by the IRB.

**Consent for publication**

Not applicable.

**Competing interests**

The author’s declare no conflict of interest.

**Author details**

1Laboratory of Clinical Virology, Institut Pasteur, University Tunis-El Manar, Tunis, Tunisia. 2Laboratory of Bioinformatics, Biomathematics and Biostatistics (BIMS), Institut Pasteur Tunis, Tunis, Tunisia. 3Laboratory for Urgent Response to Biological Threats (CIBU), Environment and Infectious Risks (ERI) research expertise unit, Institut Pasteur, Paris, France. 4National Observatory for New and Emerging Diseases, Ministry of Health, Tunis, Tunisia. 7Faculty of Medicine, University Tunis-El Manar, Tunis, Tunisia.

**Received**: 24 June 2020 Accepted: 5 July 2021

**Published online**: 14 July 2021

**References**

1. Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020;92(4):418–23.

2. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. J Med Virol. 2020;92(4):401–2.

3. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China. 2019. New Engl J Med. 2020;382:727–33.

4. World Health Organization (WHO). Coronavirus disease 2019 (COVID-19) Situation Report – 52. Geneva: WHO; 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200312-sitrep-52-Covid-19.pdf?sfvrsn=2bfc9c0_4

5. World Health Organization (WHO). Coronavirus disease 2019 (COVID-19) Situation Report – 131. Geneva: WHO; 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200621-Covid-19-sitrep-153.pdf?sfvrsn=c89464d4_2

6. World Health Organization (WHO). Coronavirus disease 2019 (COVID-19) Situation Report – 43. Geneva: WHO; 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200303-sitrep-43-Covid-19.pdf?sfvrsn=7e6425ed_2

7. National Observatory of New and Emerging Diseases. COVID-19 in Tunisia: situation update on June 7th, 2020 [In french]. http://www.onmenir.tn/fr/IMG/pdf/COVID-19-dernier-bulletin.pdf.

8. Yin C. Genotyping coronavirus SARS-CoV-2: methods and implications. Genomics. 2020;112:3588.

9. Stefaneli P, Faggioni G, Lo Presti A, et al. Whole genome and phylogenetic analysis of two SARS-CoV-2 strains isolated in Italy in January and February 2020: additional clues on multiple introductions and further circulation in Europe. Euro Surveill. 2020;25(13):200365.

10. Wang C, Liu Z, Chen Z, et al. The establishment of reference sequence for SARS-CoV-2 and variation analysis. J Med Virol. 2020;92(6):667–74.

11. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3):200045.

12. Kumar S, Stecher G, Tamura K. MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets. Mol Biol Evol. 2016;33(7):1870–4.